{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-061875","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.598532+00:00","generated_at":"2026-05-18T22:59:38.662489+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Liminatus Pharma provides update on lead asset IBA101; IND filing H2 2025","bullets":["IBA101 is a next-generation CD47 blockade designed to avoid anemia and thrombocytopenia seen with first-generation drugs.","Preclinical data show IBA101 plus PD-1/PD-L1 inhibitors gave 2-3x higher complete response rates vs monotherapy.","IND preparation begins H2 2025 with simultaneous submissions to U.S. FDA and Korea MFDS planned.","Phase 1 first-in-human study in advanced solid tumors (starting with NSCLC) expected to launch in late 2026.","Company completed SPAC merger with IRIS Acquisition Corp. and began trading on Nasdaq in May 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-061875","json":"https://secwatch.observer/filing/0001104659-25-061875.json","markdown":"https://secwatch.observer/filing/0001104659-25-061875.md","text":"https://secwatch.observer/filing/0001104659-25-061875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925061875/0001104659-25-061875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925061875/tm2518647d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:59:38.662489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}